
**UNITED STATES
SECURITIES AND EXCHANGE COMMISSION**
WASHINGTON, D.C. 20549

FORM 8-K

**CURRENT REPORT PURSUANT TO
SECTION 13 OR 15(D) OF THE
SECURITIES EXCHANGE ACT OF 1934**

Date of Report (Date of earliest event reported): **March 9, 2016**

**21st CENTURY ONCOLOGY
HOLDINGS, INC.**

(Exact Name of Registrant as Specified in Charter)

Delaware

(State or Other Jurisdiction of Incorporation)

333-170812
(Commission File Number)

26-1747745
(I.R.S. Employer Identification No.)

2270 Colonial Boulevard
Fort Myers, Florida
(Address of Principal Executive Offices)

33907
(Zip Code)

(239) 931-7275
(Registrant's Telephone Number, including Area Code)

N/A
(Former Name or Former Address, if Changed Since Last Report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (*see* General Instruction A.2. below):

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
 - Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
 - Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
 - Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
-
-

Item 8.01 Other Events.

On March 9, 2016, 21st Century Oncology Holdings, Inc. (the “Company”) announced that its subsidiary, 21st Century Oncology, Inc. (“21C”), entered into a settlement (the “GAMMA Settlement”) with the federal government to resolve a dispute involving its clinical training in new facility locations for a state-of-the-art radiation dose calculation system used by radiation oncologists called GAMMA. The dispute involved the training protocols of certain staff in the utilization of GAMMA and was limited to early implementation and start-up activities at new facility locations across the country. 21C has agreed to pay a settlement amount of \$34.7 million as part of the GAMMA settlement. 21C fully cooperated with the federal government and has entered into the GAMMA Settlement with no admission of wrongdoing. There was no indication that patient harm was a component of the dispute and the Company is not aware of harm to any patient related to this dispute. The GAMMA Settlement resolves the GAMMA investigation matter disclosed by the Company in its prior SEC filings.

On March 9, 2016, the Company issued a press release regarding the GAMMA Settlement. A copy of the press release is attached hereto as Exhibit 99.1 and incorporated herein by reference.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits.

| Exhibit Number | Description |
|-----------------------|--------------------|
| 99.1 | Press Release |

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

21st CENTURY ONCOLOGY HOLDINGS, INC.

Date: March 9, 2016

By: /s/ LeAnne M. Stewart
Name: LeAnne M. Stewart
Title: Chief Financial Officer

EXHIBIT INDEX

| Exhibit Number | Description |
|---------------------------|--------------------|
| 99.1 | Press Release |

FOR IMMEDIATE RELEASE

March 9, 2016

Ellen Almond 202-271-0234

Statement from 21st Century Oncology

21st Century Oncology, the nation's leading provider of integrated cancer care services, has entered into a settlement with the federal government to resolve a dispute related to clinical training in new facility locations for a radiation therapy test used by radiation oncologists called GAMMA. 21st Century Oncology fully cooperated with federal officials and has agreed to the settlement with no admission of wrongdoing. Further, there was no harm to any patient related to this dispute, nor was the issue of patient harm ever a component of the dispute.

The GAMMA tool is a state-of-the-art radiation dose calculation system developed by 21st Century Oncology and implemented by our physicians to optimize patient outcomes. We regard GAMMA as an invaluable tool that helps identify potentially adverse variances by ensuring that the radiation dose delivered to the tumor is accurate throughout the course of treatment and minimizes the potential of over or under-dosing of tumor targets. The ability to measure the actual dose delivered for every treatment compared to the expected dose enhances the safety and effectiveness of radiation therapy.

Tumors in the body are not static entities during treatment, and oncologists universally recognize that the radiation dose delivered to tumors can deviate from the original treatment plan due to anatomic changes that occur. These changes include tumor shrinkage, tumor movement from breathing, and changes in patient weight, among other factors. GAMMA allows physicians to change or adapt the treatment plan based on GAMMA calculations, enabling the physician to administer the highest quality of care for the cancer patient.

The dispute involved the training protocols of certain staff in the utilization of GAMMA, and was limited to its early implementation and startup activities at new facility locations across the country. The company implemented GAMMA across all centers to ensure every patient had access to this technology.

Our implementation efforts are and always have been consistent with 21st Century Oncology's primary goal of providing high quality patient care. We fully support our physicians' ability to determine what diagnostic and treatment tools should be utilized for each patient. To that end, 21st Century Oncology will continue to utilize the GAMMA tool across our network to help provide uniquely efficient radiation therapy to our patients.

A part of our commitment to quality, 21st Century Oncology has further enhanced our comprehensive compliance, auditing and training programs to ensure transparency and the delivery of the highest quality, most clinically appropriate care to our patients. Only those services that meet the complex Medicare and Medicaid billing criteria are submitted for reimbursement.

About 21st Century Oncology

21st Century Oncology is the largest global, physician led provider of Integrated Cancer Care services. The company offers a comprehensive range of cancer treatment services, focused on delivering academic quality, cost-effective patient care in personal and convenient settings. As of December 31, 2015, the company operated 181 treatment centers, including 145 centers located in 17 states and 36 centers located in seven countries in Latin America. The company holds market-leading positions in most of its domestic local markets and abroad.
